Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Siddiqi. Ahmed Kamal AK; Khan. Muhammad Shahzeb MS; Kulkarni. Anandita A; Hall. Michael E ME; Böhm. Michael M; Díez. Javier J; Butler. Javed J
Key Findings
- SGLT2 inhibitors consistently reduce office systolic/diastolic BP by ~2.5‑4.0/1.5‑2.0 mmHg.
- Typical GLP‑1 receptor agonists lower systolic BP modestly (1.8‑5.1 mmHg) with minimal diastolic effect.
- Tirzepatide produces a markedly larger systolic BP drop (~10.6 mmHg) in selected populations.
Practical Outcomes
- For biohackers aiming to lower blood pressure while managing weight or glucose, adding tirzepatide (or a SGLT2 inhibitor) could be a useful adjunct, especially if you already have diabetes, heart failure, or chronic kidney disease. Start with low doses and monitor BP and kidney function closely, as the diuretic‑like effect can amplify BP reductions. Combining these agents with lifestyle measures (low‑salt diet, exercise) may allow you to reduce reliance on traditional antihypertensives.
Summary
The review shows that drugs normally used for diabetes, especially tirzepatide, can also drop blood pressure. SGLT2 inhibitors lower systolic pressure by about 2‑4 mmHg, while most GLP‑1 agonists only shave off 1‑5 mmHg. Tirzepatide stands out, cutting systolic pressure by roughly 10 mmHg in some high‑risk groups, making it a promising add‑on for people looking to improve heart health alongside metabolic goals.
Abstract
Hypertension is the leading modifiable risk factor for cardiovascular disease. Despite multiple antihypertensive therapies, blood pressure (BP) control remains suboptimal in many individuals with persistent cardiovascular risk. This review evaluates the antihypertensive potential of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in patients with comorbid diabetes, HF, CKD or resistant hypertension. SGLT2-i consistently lower office SBP/DBP (2.5-4.0/1.5-2.0 mmHg) and 24-hour ambulatory BP (3.8/1.8 mmHg). GLP-1RAs show modest SBP reductions (1.8-5.1 mmHg) and minimal DBP effects (~ 0.5 mmHg), though tirzepatide shows greater efficacy (~ 10.6 mmHg) in select populations. Both classes have demonstrated cardio-renal benefits, favorable safety profiles, and reduced polypharmacy. SGLT2-i exert more consistent BP-lowering effects than GLP-1RA, largely due to their diuretic-like action. While not first-line therapies, both drug classes show promise as adjuncts in high-risk populations. Future research should further define their role in comprehensive hypertension management.
Study Information
pubmed
2025
2025-12-01T00:00:00.000Z
10.1007/s11906-025-01342-7
94